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Pancreatic cancer is an aggressive cancer of the digestive system, which is becoming a 
serious health problem worldwide. Overall survival for patients with pancreatic cancer is 
poor, mainly due to a lack of biomarkers to enable early diagnosis and a lack of prognostic 
markers that can inform decision-making, facilitating personalized treatment and an optimal 
clinical outcome. ncRNAs play an important role in pancreatic carcinogenesis. Here we 
review the literature on the role of ncRNAs as biomarkers in pancreatic cancer. We focus 
on the significance of ncRNAs as markers for early diagnosis, as prognostic biomarkers 
able to inform clinical management and as targets for novel therapeutics for patients with 
pancreatic cancer.
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Pancreatic cancer
Pancreatic cancer (PC) is one of the leading causes of death around the world [1]. Early diagnosis is 
frequently missed. Current imaging technologies have failed to detect early PC, and the absence of 
specific and sensitive biomarkers has limited the possibility of cost-effective screening for sporadic 
PC. About 9000 new diagnoses of PC are made in the UK each year, and >7000 of these patients 
live in England. Sadly, deaths from PC are as high as the diagnoses. Indeed, <5% of patients with 
pancreatic cancer are alive after 5 years, and even in patients amenable to surgical resection the 
5-year survival rate is around 20% [2].
The most common type of PC arises from the pancreatic ductal cells and is named pancre-
atic adenocarcinoma (PDAC). In the past this was thought to be a homogeneous disease, but 
Collison et al. have provided evidence that supports the division of PDAC into subtypes accord-
ing to molecular and genetic features. They identified a ‘classic’ subtype, characterized by high 
levels of expression of the adhesion-associated and epithelial genes, AGR2 and S100PBP; a ‘quasi-
mesenchymal’ subtype, which expresses the mesenchyme-associated genes twist family, TWIST1 
and S100A2 at high levels and an ‘exocrine-like’ subtype, in which genes involved in the digestion 
process such as REG3A and PRSS1 are highly expressed. These molecular subtypes have been 
shown to differ in clinical outcome and treatment response [3]. Recently, Bailey et al. delineated 
four new subtypes of PDAC based on data obtained from the RNA expression profiling of 456 
PDAC patients: the ‘squamous’, the ‘progenitor’, the ‘immunogenic’ and the ‘aberrantly differenti-
ated endocrine exocrine’, which are characterized by their various histopathological peculiarities 
and different overall survival (OS) [4]. Sequencing analyses have confirmed the heterogeneity of 
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PDAC, indicating the potential for identifying 
independent subtypes with specific mutations 
in druggable genes [5].
It is well established that PDAC does not arise 
de novo but rather is preceded by noninvasive pre-
cursor lesions that undergo histologic and genetic 
progression culminating in invasive neoplasia. 
The most common premalignant precursors of 
PDAC are the pancreatic intraepithelial neoplasms 
(PaINs). There are different grades of PaINs, 
which are associated with different risks of inva-
sive cancer. PaIN-1a lesions are characterized by a 
flat structure, while PaIN-1b lesions show a papil-
lary architecture. Moderate to severe cytological 
abnormalities are present in PaIN-2 and -3 lesions, 
which exhibit a higher risk of malignancy. Other 
precursor lesions of PDAC include mucinous 
cystic neoplasms and intraductal papillary muci-
nous neoplasms (IPMN). IPMN is associated with 
an increased risk of malignancy, which is higher 
for the main duct and mixed forms (40–92%) but 
still present for the branch duct forms (15–25%) 
[6]. To date, the diagnosis of IPMN is made using 
imaging technologies; identifying biomarkers that 
are associated with malignant transformation is 
warranted if the clinical management of patients 
with IPMN is to improve.
Surgery represents the only treatment option 
which is potentially curative. Unfortunately, only 
20% of PDACs are diagnosed at a resectable stage. 
Unresectability is mainly due to the encroachment 
of vascular and neurological structures, which 
may also be present in small tumors given the 
dense stromal reaction to PDAC. For this reason, 
>50% of curative resections result in positive resec-
tion margins, which account for the high risk of 
relapse [7]. Adjuvant treatment with single-agent 
chemotherapy (gemcitabine or fluorouracil) has 
proved beneficial with an increase in median sur-
vival from 15 to 23 months compared with obser-
vation alone [7]. However, OS after resection is still 
poor and clinical trials are ongoing to investigate 
if combination chemotherapy can improve the 
s urvival advantage in the adjuvant setting.
The prognosis of metastatic PDAC is dis-
mal, with a median OS of about 6 months in 
the absence of any treatment. Systemic chemo-
therapy can improve this figure and has been the 
focus of clinical investigation over the last few 
years. Systemic treatment for advanced PDAC 
includes single-agent gemcitabine, a combination 
of two drugs or a combination of three drugs. 
The response rate and OS correlate with the 
number of drugs used, but unfortunately toxicity 
also significantly increases with the use of more 
drugs [2]. Increasingly, evidence is emerging that 
supports the use of second-line chemotherapy in 
patients who fail first-line treatment [2]. Thus, 
clinicians have the option of offering a triple 
combination as first line or adopting a sequential 
approach that may distribute the administration 
of the active drugs over the course of the disease, 
according to the outcome expected (neoadjuvant 
vs palliative setting).
The development of novel therapeutics can 
prompt the discovery of robust biomarkers, 
which can help to personalize treatment. Studies 
of protein-coding genes have failed to identify 
biomarkers of drug response in PDAC [8] with 
the exception of hENT1, which seems to predict 
the benefit from adjuvant gemcitabine [9]. The 
identification of predictive biomarkers in PC is 
complicated by the limited amount of material 
obtained from diagnostic cytology and the high 
level of heterogeneity within tumors. Indeed, 
efforts are being made to study ‘liquid biopsies’ 
in order to overcome these limitations [10].
Noncoding RNA
The human genome includes genes that are 
translated into proteins (protein-coding genes) 
and genes that are transcribed into RNAs but 
lack the translation into proteins (ncRNAs). 
Protein-coding genes account for around 2% 
of the genome, the majority of which is instead 
represented by ncRNAs. For several decades ncR-
NAs were considered to be junk elements of the 
genome with no function. However, over the last 
few years there has been an increasing amount of 
evidence pointing to an essential regulatory role 
for ncRNAs. ncRNAs are now known to drive 
the biological complexity of vertebrates and to 
represent important players in evolutionary and 
developmental biology [11].
ncRNAs are classified as either sncRNAs, 
usually 20–30 nucleotides (nt) in length, or 
lncRNAs, >200 nt in length. The class of sncR-
NAs consists of different molecules involved in 
the mechanism of RNA interference, such as 
miRNAs, siRNAs, piRNAs and tiRNAs.
miRNA molecules are small ssRNAs con-
sisting of 18–22 nt, which modulate the post-
translational expression of several genes [12]. The 
biosynthesis of miRNAs starts in the nucleus and 
is completed in the cytoplasm. The first step is 
mediated by RNA polymerase II, and leads to the 
transcription of the primary miRNAs: long mol-
ecules characterized by a 5′ 7-methyl-guanylate 
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cap and a 3′ poly(A) tail. These long molecules are 
several kilobases in length and are subsequently 
cleaved by the RNase III complex into 60–100 nt 
hairpin structures, called precursor miRNAs (pre-
miRNA). The pre-miRNAs are transported from 
the nucleus to the cytoplasm by Exp5 proteins. In 
the cytosol, the pre-miRNAs are sliced by Helicase 
MOI into miRNA double strands. The two 
strands of each duplex are separated by helicases, 
and the nonfunctional strand is destroyed [12]. 
The mature functional strand is loaded into the 
RNA-induced silencing complex with hAgo, the 
catalytic component which promotes the base-
pairing between the 5′-region of the miRNA 
and complementary target sites within mRNA 
– primarily the 3′ untranslated region [13]. The 
miRNA:mRNA base-pairing takes place through 
a short ‘seed-region’. If the miRNA:mRNA base-
pairing is strong, the hAgo protein removes the 
mRNA poly-A-tail and exposes the molecule to 
exonucleases for degradation. If the base-pairing is 
less extensive the first direct effect is the inhibition 
of translation and then, probably, the mRNA is 
carried to the P-bodies and sequestered by ribo-
somes for degradation. Sometimes more than one 
miRNA is needed to bind the same mRNA and 
reduce its translation [13].
lncRNAs are sequences longer than 200 nt, 
transcribed by RNA polymerase II. Their genes 
are mainly located in intronic and intergenic 
regions, although in some cases they can over-
lap protein-coding genes. On the basis of their 
proximity to protein-coding genes lncRNAs can 
be classified as: antisense; sense; bidirectional; 
intronic; and intergenic lncRNAs. Most have 
the same structures as mRNAs, such as a 5′ cap 
and a 3′ poly(A) tail. lncRNAs can assume a sec-
ondary structure and can be localized in both 
the nucleus and the cytoplasm [14]. They can 
also undergo splicing at their 5′ and 3′ ends to 
generate circRNAs [15]. They are characterized 
by a paucity of introns and a low GC content, 
which accounts for their low level of expres-
sion within the cell. Intergenic and antisense 
lncRNAs were deemed to be more stable than 
other types of lncRNAs [16]. Several functions 
have been hypothesized for lncRNAs. They can 
act as cis- or trans-regulators of gene activity, 
as scaffold elements for chromatin-modifying 
complexes, as gene enhancers or as ceRNAs [17].
miRNAs in PC
Despite their small size, endogenous miRNAs 
have been shown to have a remarkable effect on 
protein-coding gene expression. The deregulation 
of miRNA profiles has been implicated in several 
tumors. miRNAs can act as either tumor sup-
pressors or oncogenes. Downregulation of tumor- 
suppressor miRNAs can promote the upregula-
tion of genes involved in cancer progression, 
whereas overexpression of oncogenic miRNAs 
can elicit the downregulation of genes, which sup-
press tumor development. miRNA deregulation 
can be easily monitored by miRNA profiling and 
has offered new clues to understand pancreatic 
tumorigenesis.
The first evidence for miRNA deregulation in 
human PDAC came from expression-profiling 
studies, which identified several miRNAs aber-
rantly expressed in human PDAC in comparison 
to adjacent tissues, including miR-155, miR-21, 
miR-22/miR-222, miR-10 and miR-181 [18–21]. 
Identification of mRNA targets as key regula-
tors of cell behavior confirmed the role played by 
miRNAs in the pancreatic carcinogenic process 
(Table 1).
lncRNAs in PC
A novel role for lncRNA in PC has come to light 
in recent studies that have investigated the dysreg-
ulation of lncRNA in PC tissues compared with 
normal tissues (Table 2). These studies have high-
lighted higher levels of H19 [37], HOTAIR [38], 
HOTTIP [39] and MALAT-1 [40] in PC tis-
sues. PVT1 [41,42], HULC [43], AF339813 [44], 
LOC389641 [45] and AFAP1-AS1 [46] also appear 
to be upregulated in PDAC. Conversely, GAS5 
and ENST00000480739 were found to be down-
regulated in PDAC tissues compared with normal 
pancreatic tissues [47,48]. Nevertheless, the exact 
mechanism of action of these ncRNAs in PDAC 
remains to be fully elucidated. Gao et al. have sug-
gested that the lncRNA ROR can act as a ceRNA 
in PC cells [49]. 
Biomarkers in pancreatic adenocarcinoma
A biomarker is “a characteristic that is objectively 
measured and evaluated as an indicator of nor-
mal biological processes, pathogenic processes 
or pharmacologic responses to a therapeutic 
intervention.” There has been a growing effort 
to address the study of circulating biomarkers in 
PDAC, with the aim of identifying a noninvasive, 
reproducible, cost-effective biomarker that can be 
easily monitored over the course of the disease. 
To improve the clinical management of PDAC 
patients, a diagnostic biomarker that increases 
at the outset of the disease that can aid in early 
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diagnosis, a prognostic factor that can address 
the need for adjuvant treatment and a predictive 
biomarker of response to chemotherapy are all 
needed. In addition, a blood-based marker would 
enable clinicians to follow tumor evolution, rep-
resent a surrogate marker for tumor heterogeneity 
and provide information from nonbiopsiable sites 
such as those with peritoneal carcinosis. To date, 
the only biomarker available for PDAC is Ca19-9. 
This antigen is overexpressed in 80% of patients 
with PC. However, its specificity for PDAC is 
poor and therefore its use as diagnostic biomarker 
is not recommended [58]. Ca19-9 has the poten-
tial to identify aggressive tumors and a decline in 
Ca19-9 after one cycle of chemotherapy may iden-
tify patients who would benefit from g emcitabine 
chemotherapy [59].
ncRNAs as diagnostic biomarkers
miRNAs can circulate in the blood as free RNAs, 
which are bound to hAgo2, or included in 
exosomes; in either cases they are stable and they 
can be easily detected in patients’ biofluids [60]. 
Several authors have attempted to study the diag-
nostic value of circulating miRNAs in PDAC. The 
largest study looked at 409 patients with PC, 25 
with chronic pancreatitis and 312 healthy par-
ticipants [61]. 90% of PDAC patients were unre-
sectable. In these cases whole blood was collected 
before the patients started chemotherapy, while in 
resectable cases sampling was undertaken before 
surgery. More than 700 miRNAs were tested in 
the discovery cohort, which included 141 cases of 
confirmed PDAC. Among the 38 miRNAs that 
differentiated patients with PDAC from those with 
chronic pancreatitis (n = 17) and healthy controls 
(n = 68) in the discovery cohort, 19 were validated 
in the training cohort (180 PDAC vs 199 healthy 
controls) and nine miRNAs were found to be con-
sistently deregulated in the discovery, training and 
validation cohorts. These miRNAs were used to 
derive a diagnostic index based on miR-145, miR-
150, miR-223 and miR-636. The sensitivity and 
specificity of this diagnostic miRNA panel were 
not superior to Ca19-9, but the combination of 
this index with Ca19-9 significantly enhanced the 
AUC when compared with Ca19-9 alone (AUC 
0.93 vs 0.89) [61]. Interestingly, this index signifi-
cantly correlated with the white blood cell, gran-
ulocyte and platelet count. Although this is not 
surprising, given that the analysis was performed 
on whole blood samples, it underlines the fact that 
the level of free miRNAs in the blood is much 
lower than the level detectable in cells. Therefore, 
great caution should be applied when choosing 
the source of the samples and the method of sam-
ple processing. Despite the fact that whole blood 
is easy to collect in clinical practice and using it 
Table 1. miRNAs involved in the pathogenesis and progression of pancreatic cancer.
miRNA Deregulation Source Biological process Targets Ref. 
miR-21/miR23a/miR-27a  Up Human cell lines (PANC-1, MiaPaCa-2, 
LPc006, PLc167), xenograft models
Invasion, cell growth, 
proliferation, apoptosis
PDCD4, BTG2, 
NEDDL4, PTEN
[22–
24]
miR-10b Up Human cell lines (PANC-1), human plasma Invasion TIP30, p16 [25,26]
miR-221/miR-222 Up Human cell lines (BxPC-3, MiaPaCa-2,  
PANC-1, SW1990), human tissues
Proliferation, invasion, 
apoptosis
MMP-2, MMP-9 [27]
miR-155 Up Human cell lines (MiaPaCa-2) Apoptosis TP53INP1 [28]
miR-193b Down Human cell lines (AsPC-1, PANC-1, CFPAC-1, 
Hs766T, SW1990, Mia PaCa-2, BxPC-3)
Apoptosis, cell-cycle 
progression, invasion
MIR31HG [29]
miR-494 Down Human cell lines (AsPC-1, PANC-1), xenograft 
models
Proliferation, migration, 
invasion, gemcitabine 
sensitivity
FOXM1, beta-catenin [30]
Let-7 Down Human tissues Proliferation KRAS, MAPK [31,32]
miR-206 Down Human cell lines (PANC-1, BxPC-3, 
MiaPaca-2, CFPAC-1, Colo357, Capan-1), 
human tissues, xenograft models
Invasion, migration, 
proliferation, cell-cycle 
progression
KRAS, ANXA2 [33]
miR-615-5p Down Human cell lines (BxPC-3, CFPAC-1, SW1990, 
PANC-1), human tissues, xenograft models
Migration, invasion, 
proliferation, tumor 
growth
IGF2 [34]
miR-219-1-3p Down Human cell lines (Capan-1, Capan-2, BxPC-3, 
PANC-1 and MiaPaCa-2), human tissues
Migration, proliferation, 
tumor growth
MUC4 [35]
miR-124 Down Human cell lines (BxPC-3, CFPAC-1, SW1990, 
PANC-1), human tissues, xenograft models
Proliferation, invasion, 
metastasis
Rac1 [36]
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avoids the need for extra steps and centrifuga-
tions, the information derived from whole blood 
may be different from the information derived 
from plasma and/or serum, which may better 
reflect the portion of free (or exosome-related) 
miRNAs and potentially be used as tumor sur-
rogates. Li et al. identified miR-1290 in the serum 
of PDAC patients and observed that it had a higher 
diagnostic accuracy than Ca19-9 in their cohort 
(AUC 0.86 vs 0.77 in the group PDAC vs healthy 
controls) and was also expressed in tumor tissue, 
where it had prognostic significance [62]. Several 
other studies have found that circulating miRNAs 
or panels of miRNA found in the plasma and/or 
serum of PDAC patients have diagnostic potential 
and can improve upon the accuracy of Ca19-9 in 
diagnosis [63–65]. In selected cases salivary miR-
NAs were found deregulated in early PDAC [66]. 
However, the lack of concordance among these 
small studies represents the main challenge in 
implementing miRNA-based diagnostic tests 
in clinical practice. There are two likely reasons 
for this discordance: the normalization methods 
employed; the contribution of other medical con-
ditions to the deregulation of circulating miRNAs. 
Standard reference genes used for the normaliza-
tion of miRNA expression in tissues are not suit-
able for biofluid analysis [67], as this would imply 
the presence of whole cells in the biofluid. More 
recently, authors have attempted to normalize the 
expression of circulating miRNAs to one or a panel 
of other miRNAs. Unfortunately it is often the 
case that the expression of the miRNAs selected 
as reference genes is not consistent between sam-
ples, indicating that they may be involved in the 
pathogenetic mechanisms of the disease that the 
work is aiming to detect. For instance, miR-1228 
was used as reference gene in the profiling of cir-
culating miRNAs in liver cancer [68], and a few 
years later it was shown to modulate hepatocel-
lular carcinoma (HCC) development having been 
shown to be altered in the sera of hepatocellular 
carcinoma patients [69]. Our view is that levels of 
circulating RNAs (like circulating tumor DNA 
or circulating proteins) must be normalized to 
the volume of biofluid, as our aim is to detect the 
amount of a certain element (miRNA in this case) 
in the fluid of an individual, which is not related 
to the number of cells present in the fluid. Indeed, 
miRNAs may derive not only from broken cells 
but also from a direct release of miRNAs from 
tissues. In addition, in the case of miRNAs that 
are released from dying circulating tumor cells 
it is reasonable to speculate that these miRNAs 
may be more stable in the circulation than other 
long RNAs. The other main limitation for the use 
of circulating miRNAs as diagnostic markers is 
the specificity for the tumor. Despite a growing 
amount of evidence supporting a link between the 
load of miRNAs in the tumor and the abundance 
of circulating miRNAs [70], we cannot forget 
that a number of other medical conditions may 
Table 2. lncRNAs involved in the pathogenesis and progression of pancreatic cancer.
lncRNA Deregulation Source Biological process Ref. 
MIR31HG Up Human cell lines (AsPC-1, PANC-1, CFPAC-1, Hs766 T, SW1990, 
MiaPaCa-2, BxPC-3)
Cell growth, apoptosis, cell-cycle 
progression, invasion
[29]
LOC389641 Up Human cell lines (SW1990, AsPC-1, PANC-1, MiaPaCa-2, 
BxPC-3, Capan-2), human tissue
Progression [45]
AFAP1-AS1 Up Human cell lines (SW1990, PANC-1, MiaPaCa-2, BxPC-3, 
Capan-2, HPDE6), human tissues
Proliferation, migration, invasion [46]
HOTTIP Up Human cell lines (SW1990, PANC-1, MiaPaCa-2, BxPC-3, 
Capan-2)
Cell progression, gemcitabine 
resistance
[39,50]
PVT1 Up Human cell lines (AsPC-1) Gemcitabine sensitivity [41,42,51]
HOTAIR Up Human cell lines (PANC-1, Capan-2, SW1990, BxPC-3, 
MiaPaCa-2)
Radiosensitivity [38,52]
H19 Up Human cell lines (AsPC-1, PANC-1, CFPAC-1, SW1990, BxPC-3), 
human tissues
Metastasis, invasion, migration [53]
HULC Up Human tissues Metastasis vascular invasion [43]
MALAT-1 Up Human cell lines, (BxPC-3, CFPAC-1, CAPAN-1, SW1990,  
AsPC-1, PANC-1, HS766T), human tissues
Cell growth, migration, invasion [40,54–57]
ENST00000480739 Down Human cell lines (AsPC-1, BxPC-3, CFPAC-1, PANC-1, SW1990, 
HPNE), human tissues
Invasion [48]
GAS5 Down Human cell lines (BxPC-3, PANC-1, AsPC-1, and Hs766T), 
human tissues
Proliferation [47]
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contribute to the profile of circulating miRNAs, 
such as liver and kidney injuries [71], sepsis [72], 
cardiovascular disease [73] and immunological 
disorders [74].
The expression of miRNAs in pancreatic tis-
sue may also prove to be a useful marker when 
attempting to make a differential diagnosis in 
challenging cases. miR-196 is upregulated in 
PaIN-2/3 lesions and may help identify lesions 
with a higher risk of transformation [75,76]. miR-
21 and miR-155 are upregulated in PDAC com-
pared with adjacent tissue [19], and deregulation is 
also seen early on in IPMN, suggesting that these 
miRNAs may be considered as markers of trans-
formation [77,78]. Studies designed to determine if 
the analysis of liquid from IPMN cysts can help 
in clinical decision-making are ongoing [79]. Of 
note, a recent analysis of miRNA expression in 55 
endoscopic ultrasound-guided fine needle aspira-
tion biopsies found that miR-21 and miR-155 lev-
els could be used to differentiate malignant from 
benign lesions with a greater accuracy than stand-
ard pathology. However, comparison with other 
biomarkers (such as CEA) was not possible [80]. 
Another clinical challenge is making a differen-
tial diagnosis between PDAC and bile duct can-
cers. Collins et al. have identified miRNAs with 
disease-specific patterns of expression that may 
prove of benefit for such diagnostic purposes [81]. 
However, to date, none of these miRNA-based 
investigations have entered clinical practice as 
more validation is needed in large cohorts with 
comparable techniques.
ncRNAs as prognostic biomarkers
miRNAs can modulate a plethora of protein-
coding genes that are involved in the develop-
ment, progression and metastatic spread of PDAC 
cells [22,82]. As a result, the potential for miRNAs 
to be used as prognostic markers in PDAC has 
been extensively studied. A number of reports 
have shown a correlation between miRNAs 
and OS in resected or inoperable PDAC, with 
miR-21 observed in multiple studies. Recently, 
Frampton et al. performed a meta-analysis of 20 
studies, including >1500 patients [23]. This sug-
gests that miR-21 may represent a good candidate 
to be validated in prospective cohorts. Thirteen 
studies concluded that miR-21 has a prognostic 
significance as a predictor of survival in PDAC. 
miR-21 was still associated with significantly 
poorer clinical outcomes even after the authors 
corrected for publication bias. In patients with 
resected PDAC, high expression of miR-21 could 
identify a risk of relapse and a response to adjuvant 
gemcitabine [23]. This suggests that miR-21 may 
represent a good candidate for validation in pro-
spective cohorts. A statistically significant associa-
tion was also observed for a few other miRNAs, 
even though these were investigated in a lower 
number of studies. Most notably, the downregula-
tion of miR-34 was associated with a decrease in 
OS, consistent with previous evidence supporting 
the oncosuppressor role of this miRNA and its 
link with p53.
Based on published evidence, the assessment of 
miRNA expression in the tissue of resected PDAC 
may represent a feasible and promising marker 
for the identification of candidates amenable to 
adjuvant treatment. However, the assessment of 
miRNA expression may be more challenging in 
inoperable patients in which tissue availability is 
limited. Nonetheless, if the global deregulation 
of circulating miRNAs can be used as a surro-
gate measure of tumor features, as well as of the 
general comorbidities of a patient, it is likely to be 
a promising prognostic and predictive biomarker 
for patient selection [83–88]. We have proved that 
plasma levels of miR-21 can identify patients 
with particularly aggressive locally advanced 
PDAC who may not be suitable for a combina-
tion approach with chemoradiotherapy [70]. An 
increase in specific serum miRNAs was associ-
ated with resistance to lapatinib and capecitabine 
treatment in patients who have previously failed 
first-line chemotherapy [89], suggesting that miR-
NAs could be used as markers of different phases 
in PDAC evolution. Chemoresistance is a complex 
process that accounts for the low survival rate in 
PDAC patients. Cellular and stromal factors play 
a major role in drug resistance in PDAC. Indeed, 
miR-21 expression was shown to affect chem-
oresistance, not only by modulating cancer cell 
biology [24,90], but also by impacting on cancer-
associated fibroblasts (CAF). Indeed, miR-21 
is overexpressed both in PDAC cells and CAF 
within human PDAC, but only CAF-associated 
miR-21 was found to be associated with a response 
to fluorouracil in the RTOG 9704 trial [91].
Recent studies have shone a spotlight on a set of 
lncRNAs that could have a prognostic role in PC. 
HOTAIR is a lncRNA with pro-oncogenic activity 
in several tumors. The overexpression of HOTAIR 
was observed in PDAC human tissues associated 
with a poorer clinical outcome. In vitro data con-
firmed that this lncRNA is able to modulate cell 
proliferation and invasiveness [38]. MALAT-1 
is known to be an oncogenic lncRNA in other 
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solid tumors [54]. Pang et al. looked at the expres-
sion of MALAT-1 in 126 human PDAC tissues 
and observed that MALAT-1 was overexpressed 
in most cases of PDAC, where it represented an 
unfavorable prognostic marker independent of 
clinical stage, tumor size, lymph node metastasis 
and distant metastasis [55]. In support of these find-
ings, MALAT-1 was found to be involved in the 
induction of a stem cell-like phenotype and in the 
regulation of cell migration and invasion in PDAC 
cells [40,56,57]. lncRNAs have been shown to be 
involved in the pathogenesis of PDAC. However, 
their value as clinical biomarkers has not been 
evaluated yet and future studies are warranted to 
address this topic.
ncRNAs therapeutic targets
Recently miRNA delivery systems have been 
tested, alone and in combination with chemo-
therapeutic agents, to determine if it is possible 
to introduce miRNA therapeutics into biological 
systems in order to suppress PC. Liposomal nano-
particles carrying miR-34a or miR-143/miR-145 
[92], and polymeric nanoformulations delivering 
miR-150 [93], proved able to inhibit pancreatic 
tumor growth in vitro and in vivo. Conversely, 
experiments using antisense oligonucleotides 
(ASOs) to target the main oncomiRs upregu-
lated in cancer have confirmed the involvement 
of these oncogenic miRNAs in tumorigenesis. 
Administration of miR-21 ASOs [94] and miR-221 
ASOs [95] resulted in a reduction in cancer cell 
proliferation, migration and chemoresistance in 
PC cells in vitro and in vivo in murine PC models. 
Interestingly, the co-administration of these ASOs 
significantly enhanced their effect [96]. Other stud-
ies have revealed that the co-administration of 
miRNA-mimics or anti-miRs and chemothera-
peutics decrease the chemoresistance in PC. The 
administration of miR-205–gemcitabine conju-
gated micelles was shown to enhance the chemo-
sensitivity of gemcitabine-resistant pancreatic cell 
lines and in vivo xenograft models, while reduc-
ing tumor proliferation and growth in vitro [97]. 
Transfection with miR-17-5p ASOs has also been 
identified as a potential approach for improving 
chemosensitivity to gemcitabine in vitro [98]. H19 
regulatory sequences have been shown to have a 
potential role in pancreatic treatment, alone or 
in combination with gemcitabine [53]. HOTTIP, 
HOTAIR and MALAT-1 knockdown increases 
the sensitivity of tumorigenic cells to gemcitabine 
in vitro and in in vivo xenograft models, suggesting 
that ncRNA-based therapeutics might be used in 
adjunction with conventional chemotherapeutic 
drugs to enhance their effect.
miRNA-based therapeutics have been investi-
gated in humans and have been shown to be safe 
and efficacious in the treatment of hepatitis infec-
tion [99]. In animal models, inhibition or enforced 
expression of ncRNAs was shown to be feasible, 
safe and effective against cancer. Clinical trials 
of miRNA-based therapies in cancer patients are 
ongoing and it is likely that advances in technol-
ogy will enable the selective delivery of ncRNAs 
(through nanoliposomal particles or viral vectors) 
to expand the current phase of investigation into 
miRNAs as therapeutics for the treatment of 
human disease. However, in all cases more effort 
is needed to identify and validate an appropriate 
ncRNA candidate in large and multiple studies.
Conclusion
PDAC is a deadly disease that kills around 9000 
people in the UK each year. Through the study of 
ncRNAs in PDAC we have gained an insight into 
the pathogenetic mechanisms underlying PDAC, 
opening the way to improved strategies for the 
clinical management of PDAC patients. A num-
ber of studies have highlighted the potential of 
ncRNAs as prognostic and predictive biomarkers, 
enabling a personalized clinical approach. If circu-
lating miRNAs show some limitations as diagnos-
tic markers due to a lack of specificity, we believe 
they may represent excellent prognostic and pre-
dictive biomarkers, which could inform upon 
the interaction between tumor and host. miR-21 
expression, in particular, has consistently been 
found to correlate with clinical outcome, provid-
ing convincing evidence for taking this miRNA 
into the next step of prospective validation.
The use of ncRNAs alongside conventional 
therapeutic agents could become a promising 
approach for solving drug resistance in PC patients. 
Solid evidence has shown that miRNA-based ther-
apeutics are feasible and safe in humans [99], and 
technological developments are likely to improve 
the administration of these therapeutics.
Future perspective
The involvement of miRNA in the pathogenesis 
of PC is well supported. A growing amount of 
evidence points to the involvement of lncRNAs 
in pancreatic carcinogenesis. Long intergenic 
ncRNAs have received the greatest attention by 
the scientific community to date. However, recent 
findings suggest that other classes of lncRNAs, 
such as circular ncRNAs may represent promising 
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mediators of PDAC development and progres-
sion [100]. Their role has been extensively studied 
in other cancers, and a deeper knowledge of their 
involvement in PDAC is vital in order to identify 
candidates for use as clinical biomarkers or targets 
of therapeutics.
There is now promising data that highlight 
the potential of miRNAs to act as biomarkers 
to inform the clinical management of PDAC 
patients. We believe that miRNAs may provide 
useful information in the assessment of patients’ 
prognosis and selection for treatment. As reviewed 
previously, the most interesting candidate so far 
is miR-21, measurement of which has the poten-
tial to stratify patients on the basis of disease 
aggressiveness and to identify the risk of relapse 
in early PDAC. Large prospective validation stud-
ies should be implemented in order to provide 
solid evidence for the potential incorporation of 
ncRNA-based biomarkers in clinical practice. The 
assessment of miRNAs in resected tissue speci-
mens may be performed through a range of tech-
nologies including PCR-based technologies and in 
situ hybridization. While PCR-based technologies 
have the advantage of specificity, they pose the 
challenge of setting a threshold to be used in a pro-
spective fashion. In contrast, in situ technologies 
enable visualization of the ncRNA signal and pro-
vide a semiquantitative measurement of ncRNA 
expression that can be used to stratify patients in 
analogy to standard-of-care technologies such as 
immunohistochemistry and FISH. Conversely, in 
advanced PDAC we believe that the assessment 
of circulating ncRNAs may represent a valuable 
tool. If miR-21 again represents a good candidate 
to assess patients’ prognosis, we suggest further 
studies to identify selected ncRNAs that predict 
response to different chemotherapeutic regimens. 
Preclinical evidence supports the involvement of 
ncRNAs in the modulation of the response to 
treatment and provides a rationale for studying 
ncRNAs as biomarkers of response in human 
patients. It is likely that the investigation of 
 miRNAs in prospective large Phase III clinical tri-
als represents the best and only strategy to define 
their role as prognostic and predictive biomarkers 
in PDAC, and, eventually, to improve the clinical 
management of PC patients.
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EXECUTivE SUMMARY
Pancreatic cancer
 ●  Pancreatic cancer is a deadly disease with poor clinical outcome.
 ●  Diagnosis is often late because of the lack of biomarkers.
 ●  Surgery is the only treatment that is potentially curative. Chemotherapy is beneficial, both single-agent and 
combination chemotherapy.
ncRNAs in pancreatic cancer
 ●  ncRNAs are encoded by genes that are transcribed into RNAs, but are not translated into proteins; they are classified as 
either sncRNAs or lncRNAs. Many ncRNAs are involved in the development of pancreatic adenocarcinoma.
 ●  The diagnostic and prognostic potential of ncRNAs has been investigated with promising results, but validation 
studies are needed before they can enter clinical practice.
 ●  Advances in ncRNAs delivery systems have increased the potential for ncRNA-based therapeutics.
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